Because the therapy-resistant cancer cells, which commonly undergo EMT, are more sensitive to ferroptosis inducers, we next investigated the effect of co-treatment of β-elemene and cetuximab on cell migration of KRAS mutant CRC cells. Here, KRAS is linked to cancer.